Otonomy is a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has two product candidates in clinical development. OTO-104 is a steroid that has completed a Phase 1b clinical trial in Meniere's disease patients. OTO-201 is an antibiotic that has recently completed a Phase 1b clinical trial in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. Otonomy is advancing both OTO-104 and OTO-201 into late-stage clinical trials. Additional product candidates are expected to target tinnitus and chronic forms of hearing loss.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/04/13 | $45,900,000 | Series C |
Aperture Venture Partners Avalon Ventures Domain Associates Novo Ventures OrbiMed Advisors Osage University Partners RiverVest Venture Partners TPG Biotech | undisclosed |
| 04/30/14 | $49,000,000 | Series D |
Ally Bridge Group Aperture Venture Partners Avalon Ventures Clough Capital Partners Domain Associates Federated Kaufmann Funds Jennison Associates Novo Ventures OrbiMed Advisors Perceptive Advisors RiverVest Venture Partners TPG Biotech | undisclosed |
